CSA Medical
CSA Medical, Inc.: A leading US provider of cryotherapy systems for precise, non-invasive tissue removal.
Founded
2008CSA Medical, Inc.: A leading US provider of cryotherapy systems for precise, non-invasive tissue removal.
Founded with a mission to advance medical treatments through innovative cryotherapy solutions, CSA Medical, Inc. specializes in the development and manufacturing of medical devices that utilize spray cryotherapy. Their flagship product, the RejuvenAir System, is designed to treat chronic obstructive pulmonary disease (COPD) with chronic bronchitis by targeting and removing unwanted tissue non-invasively. The company focuses on providing effective, minimally invasive treatment options to improve patient outcomes across the United States.
Notable figures associated with CSA Medical include experienced medical professionals and industry leaders who have driven the company's research and development efforts. The company has secured significant investment from venture capital firms dedicated to advancing healthcare technologies. Key achievements include the successful launch and clinical trials of the RejuvenAir System, which has shown promise in addressing the underlying causes of COPD with chronic bronchitis. CSA Medical's impact lies in its potential to transform the treatment landscape for millions of patients suffering from debilitating respiratory conditions.
Companies similar to CSA Medical include Cryosa, Nuvaira, Focused Cryo and Cryothermic Systems.
CSA Medical was founded in 2008.
CSA Medical's headquarters is located in Lexington, KY, US.
CSA Medical's most recent funding round was for $45.2M (USD) in February 2019.
As of Feb 7, 2019, CSA Medical has disclosed funding of $106M (USD). Undisclosed round amounts are excluded.
CSA Medical has 38 employees as of Feb 5, 2024.
